1. Deferiprone: A review of its clinical potential in iron overload in beta-thalassaemia major and other transfusion-dependent diseases;Barman Balfour;Drugs,1999
2. A new depot formulation of desferrioxamine (ICL749B) given as subcutaneous bolus injection in transfusion dependent β-thalassemic patients: Update on the dose-finding program;Cappellini,1999
3. A novel oral iron chelator (ICL670A): Update on a phase I single-dose safety study;Galanello,1999
4. Modulation of deferoxamine toxicity and clearance by covalent attachment to biocompatible polymers;Hallaway,1989
5. ICL670A: A new, potent, orally active chelator;Nick,1999